Shop HMR Foods There's no "one-size-fits-all" approach to weight loss
Our results showed that LCLT supplementation was safe and well tolerated, and may be protective, since we found a decrease in coagulation disturbance markers, as well as reduction in the severity of lung alterations when given to patients with mild COVID-19 (Cohort 2)
Some of these medications (liraglutide, semaglutide, and dulaglutide) have demonstrated cardiovascular benefits in clinical trials, with Wegovy specifically approved for reducing cardiovascular risk in adults with established cardiovascular disease and either obesity or overweight
,aspect=ignore)
MONDAY, June 8, 2026 (HealthDay News) -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with reduced risks for thromboembolic events, emergency department use, and mortality among adults with obesity and autoimmune diseases (AIDs), according to a study published online June 6 in the Journal of the American Heart Association to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.Hao Dai, Ph.D., from the Indiana University School of Medicine in Indianapolis, and colleagues conducted a retrospective cohort study, which emulated a target trial using 2014 to 2024 electronic health record data to examine the association between GLP-1 RA use and major adverse cardiovascular and thromboembolic event risk among adults with obesity and AID
The evidence remains early, but it is strong enough to guide thoughtful, real-world use
[DOI] [PMC free article] [PubMed] [Google Scholar] 183.Luo C., Peng Y., Gu J., Li T., Wang Q., Qi X., Wei A
